Boehringer Ingelheim's Lung Cancer Breakthrough Offers New Hope for Patients

Boehringer Ingelheim has developed a new drug for non-small cell lung cancer with a specific genetic mutation. The treatment offers improved efficacy and better quality of life for patients. This achievement strengthens Vienna’s reputation as a key hub for oncology research and drug development. Work on the drug began in 2017 at Boehringer Ingelheim’s Vienna research site. An interdisciplinary team led the project, cutting the usual 15-year development timeline to just eight years. The company coordinates clinical trials across over 30 countries from its Regional Center in the Austrian capital.

In August 2025, the U.S. Food and Drug Administration approved the drug. Regulatory clearance soon followed in China and Japan. Around 40,000 people worldwide receive this diagnosis annually, including many women and non-smokers.

Boehringer Ingelheim employs about 500 cancer researchers in Austria. Over the past decade, it has invested more than one billion euros in the country, with roughly 300 million euros spent yearly on research and development. Another drug for idiopathic pulmonary fibrosis is set to launch later this year, with three more oncology treatments expected by 2028. The breakthrough highlights Austria’s ability to produce high-impact medical innovations. The new drug is already available in major markets, offering hope to patients with this form of lung cancer. Further treatments from the company’s pipeline are on the horizon.